AN INNOVATIVE NEW STANDARD OF CARE
Abbott offers the world’s most comprehensive portfolio of solutions for heart failure therapy. By developing and maintaining clinical partnerships with world-renowned heart failure experts, we are continually developing innovative solutions for unmet needs. And we are dedicated to working closely with you and all of our partners to positively transform heart failure management and treatment.
Learn more about Abbott Heart Failure Solutions:
By empowering the transformation of heart failure with new standards of care—from earlier detection to short- and long-term support—we join you in the quest to help patients lead fuller lives:
MultiPoint™ Pacing with Quadra Allure MP™ CRT-P and the Quadra Assura MP™ CRT-D1 offers more options to make non-response a non-issue. Cardiac Resynchronization Therapy (CRT) Technology is capable of delivering two impulses from a single LV lead to tailor intraventricular conduction to the needs of the individual patient. MultiPoint™ Pacing is designed to deliver effective resynchronization, providing an option for patients who do not respond to traditional CRT pacing.
The CardioMEMS™ HF System, the first and only FDA-approved system for monitoring pulmonary arterial pressure to improve quality of life, reduce heart failure hospital admissions (even in patients with preserved ejection fraction) and significantly improve functional class and 6-minute walk distance for patients with NYHA Class III heart failure.2-4
HeartMate II™ LVAD, the proven and trusted LVAD offers patients with heart failure more meaningful moments and a better quality of life.5 The HeartMate II LVAD is the most widely used and extensively studied LVAD in the world.6
HeartMate 3™ LVAD with Full MagLev™ Flow Technology is a milestone in LVAD therapy—setting a standard of hemocompatibility through excellent blood handling.*,**,7-9
Merlin.net™ Patient Care Network is a remote monitoring system that imports and manages cardiac information for patients with Abbott implanted cardiac rhythm management and pulmonary artery pressure monitoring devices. Clinicians upload and manage patient-device data by accessing a web interface using the Internet and a compatible browser.
INTEGRATED HEART FAILURE SOLUTIONS AT EVERY STAGE
Abbott is focused on innovative best-in-class heart failure technologies that reflect the complex interconnectivity of the disease. We are committed to investing in the future of heart failure management and giving clinicians the proven, integrated, evidence-based tools they need to address the spectrum of patient need at every stage of disease progression.
INVESTING IN THE FUTURE OF HEART FAILURE MANAGEMENT AND TREATMENT
We are dedicated to providing ongoing and in-depth support that complements your heart failure program. And we share your goal of helping more people with heart failure lead fuller and more satisfying lives. Our investment in physicians and patients includes:
Join us to "Beat as One™" and experience first-hand our dedication to partnering with healthcare professionals to transform heart failure management and treatment through innovation, integration, and investment. Complete the form below to have an Abbott representative contact you about Abbott heart failure solutions.
*As defined by zero incidence of pump thrombosis in the MOMENTUM 3 trial at 6 months.
**The HeartMate 3 LVAD address the complex interconnectivity of hemocompatibility events by minimizing pump thrombosis without significantly impacting*** stroke or gastrointestinal bleeding.
***There is no significant difference between the HeartMate 3 and HeartMate II LVADs with regard to stroke or gastrointestinal bleeding in the MOMENTUM 3 study: 7.9% and 15.9% for the HeartMate 3 LVAD, respectively, vs 10.9% and 15.2% for the HeartMate II LVAD in the MOMENTUM 3 trial at 6 months.7
1. Zanon F, Marcantoni L. Baracca E, et al. Optimization of left ventricular pacing site plus MultiPoint Pacing improves remodeling and clinical response of cardiac resynchronization therapy at 1 year. Heart Rhythm. 2016;13(8):1644-1651. http://dx.doi.org/10.1016/j.hrthm.2016.05.015
2. Abraham WT. Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet. 2016;87(10017):453-461.
3. Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circulation: Heart Failure. 2014;7(6):935-944.
4. Alam A, Jermyn R, Joseph M, Patel S, Jorde U, Saeed O. Improved quality of life scores and exercise capacity with remote pulmonary pressure monitoring in patients with chronic heart failure. Presentation 903-06. American College of Cardiology 2016 Scientific Sessions, Chicago. April 2016.
5. Estep JD, Starling RC, Horstmanshof DA, et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients. Results from the ROADMAP study. J Am Coll Cardiol. 2015;66:1747-1761.
6. Abbott. Data on file, SJM-HM-0817-0090_Most Widely Used Reference Doc.
7. Mehra MR, Naka Y, Uriel N, et. al. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med. 2017;376:440-50.
8. Bourque K, Cotter C, Dague C, Harjes D, Dur O, Duhamel J, Spink K, Walsh K, and Burke E. Design Rationale and Preclinical Evaluation of the HeartMate 3 Left Ventricular Assist System for Hemocompatibility. American Society of Artificial Internal Organs. 2016;62:375-383.
9. Uriel N, Colombo PC, Cleveland JC, et al. Hemocompatibility-related outcomes in the MOMENTUM 3 trial at 6 months. Circulation. 2017;135(21):2003-2012.
Indications and Usage: The CardioMEMS™ HF System is indicated for wirelessly measuring and monitoring pulmonary artery (PA) pressure and heart rate in New York Heart Association (NYHA) Class III heart failure patients who have been hospitalized for heart failure in the previous year. The hemodynamic data are used by physicians for heart failure management and with the goal of reducing heart failure hospitalizations.
Contraindications: The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.
Potential Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to the following: infection, arrhythmias, bleeding, hematoma, thrombus, myocardial infarction, transient ischemic attack, stroke, death and device embolization.
Indications: The HeartMate II™ Left Ventricular Assist System is indicated for use as a “bridge to transplantation” for cardiac transplant candidates who are at risk of imminent death from non-reversible left ventricle failure. It is also indicated for use in patients with New York Heart Association (NYHA) Class IIIB or IV end-stage left ventricular failure, who have received optimal medical therapy for at least 45 of the last 60 days, and who are not candidates for cardiac transplantation. The HeartMate II Left Ventricular Assist System is intended for use both inside and outside of the hospital, or for transportation of Left Ventricular Assist Device patients via ground ambulance, airplane, or helicopter.
Contraindications: The HeartMate II Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.
Adverse Events: Adverse events that may be associated with the use of the HeartMate II Left Ventricular Assist System are listed below. Adverse events are listed in decreasing order of frequency, except for death, which appears first because it is a non-reversible complication: death, bleeding (perioperative or late), cardiac arrhythmia, local infection, respiratory failure, device malfunction, sepsis, right heart failure, driveline or pump pocket infection, renal failure, stroke, neurologic dysfunction, psychiatric episode, peripheral thromboembolic event, hemolysis, hepatic dysfunction, device thrombosis, myocardial infarction.
Refer to the User Manual for detailed indications, contraindication, warning, precautions and potential adverse events.
Indications: The HeartMate 3 Left Ventricular Assist System is indicated for providing short-term hemodynamic support (e.g., bridge to transplant or bridge to myocardial recovery) in patients with advanced refractory left ventricular heart failure.
Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.
Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are listed below. Adverse events are listed in anticipated decreasing order of frequency, except for death, which appears first as it is a non-reversible complication: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis), possible pump thrombosis (has not occurred with HeartMate 3™ in the MOMENTUM 3 short-term clinical study through 180 days).
Refer to the User Manual for detailed indications, contraindications, warnings, precautions and potential adverse events.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.